by Stratta, P. et al.
Nephrology and Transplantation, Department of Clinical and Experimental Medicine & International Research Centre Autoimmune Disease, Amedeo Avogadro University, Novara Ospedale Maggiore della Carità, USA
Nephrology and Transplantation, Department of Clinical and Experimental Medicine & International Research Centre Autoimmune Disease, Amedeo Avogadro University, Novara Ospedale Maggiore della Carità, USA
The medical community must be apprised of the concern surrounding the use of gadolinium contrast agent in patients with even moderate renal failure, considering that the number of at risk persons is 20 times greater than that of patients needing dialysis/transplantation, remember that the risk is particularly high in patients with liver transplantation in the presence of functional renal impairment, and not to forget that MR examination remains one of the three pillars of molecular medicine.
Curr. Med. Chem. 2008; 12:1229-35
